New York (AFP) – Mylan will pay $465 million to resolve accusations from regulators that it overbilled the federal Medicaid program for the EpiPen allergy medication, the drugmaker announced Friday.
The settlement with the Department of Justice and other regulators resolves questions about Mylan’s classification of EpiPen as a generic drug, Mylan said.
Regulators have said the misclassification contributed to a swelling of payments to Mylan, which nearly monopolizes the market for the allergy injectors, for EpiPen under federal health care programs.